 |
| |
| Oct-22-19 | Upgrade |
SVB Leerink |
Mkt Perform → Outperform |
|
|
| Sep-06-19 | Downgrade |
JMP Securities |
Mkt Outperform → Mkt Perform |
|
|
| Jun-27-19 | Downgrade |
SVB Leerink |
Outperform → Mkt Perform |
|
|
| May-06-19 | Initiated |
SVB Leerink |
Outperform |
$13 |
|
| Mar-28-18 | Resumed |
Leerink Partners |
Outperform |
$52 |
|
| Feb-09-18 | Initiated |
Guggenheim |
Buy |
$53 |
|
| Jun-16-17 | Initiated |
Cantor Fitzgerald |
Overweight |
$50 |
|
| Nov-29-16 | Initiated |
Leerink Partners |
Outperform |
$54 |
|
| Sep-30-16 | Initiated |
JMP Securities |
Mkt Outperform |
|
|
| Jun-10-16 | Initiated |
Guggenheim |
Buy |
$35 |
|
| Nov-02-15 | Initiated |
Jefferies |
Buy |
$20 |
|
| Nov-02-15 | Initiated |
Citigroup |
Buy |
|
|
|
|
| Mar-17-20 02:46AM | Edited Transcript of ACRS earnings conference call or presentation 25-Feb-20 10:00pm GMT Thomson Reuters StreetEvents |
| Feb-25-20 04:01PM | Aclaris Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Provides R&D and Business Highlights GlobeNewswire |
| Feb-24-20 07:31AM | Is Aclaris Therapeutics, Inc.'s (NASDAQ:ACRS) CEO Paid At A Competitive Rate? Simply Wall St. |
| Feb-19-20 05:00PM | Aclaris Therapeutics to Announce Fourth Quarter and Full Year 2019 Financial Results on February 25, 2020 GlobeNewswire |
| Feb-10-20 07:00AM | Aclaris Therapeutics to Present at the SVB Leerink 9th Annual Global Healthcare Conference GlobeNewswire |
| Jan-13-20 05:03PM | Aclaris' MK2 Inhibitor Shows Encouraging Data in Phase I Zacks |
| Jan-10-20 07:13AM | The Daily Biotech Pulse: Positive Data Readouts To Spur Aclaris, Moderna And Ultragenyx Benzinga +17.20% |
| 05:40AM | Some Aclaris Therapeutics (NASDAQ:ACRS) Shareholders Have Taken A Painful 94% Share Price Drop Simply Wall St. |
| Jan-09-20 04:27PM | Aclaris Therapeutics Announces Positive Results From Phase 1 Single and Multiple Ascending Dose Trial of ATI-450, an Investigational Oral MK2 Inhibitor GlobeNewswire |
| Jan-08-20 08:00AM | Aclaris Therapeutics Announces Appointment of Vincent Milano to Board of Directors GlobeNewswire |
| Dec-24-19 12:00PM | Aclaris (ACRS) Upgraded to Buy: Here's Why Zacks |
| Dec-12-19 10:33AM | Did Hedge Funds Drop The Ball On Aclaris Therapeutics, Inc. (ACRS) ? Insider Monkey |
| Nov-27-19 03:23PM | Shareholder Alert: Robbins LLP Announces Another Complaint Filed Against Aclaris Therapeutics, Inc. (ACRS) Business Wire |
| Nov-21-19 11:39AM | Shareholder Alert: Robbins LLP Announces Another Complaint Filed Against Aclaris Therapeutics, Inc. (ACRS) Business Wire -11.24% |
| Nov-18-19 05:34PM | Rigel Gets Positive CHMP Review for Thrombocytopenia Drug Zacks |
| Nov-17-19 07:14AM | Edited Transcript of ACRS earnings conference call or presentation 7-Nov-19 10:00pm GMT Thomson Reuters StreetEvents |
| Nov-12-19 04:01PM | Aclaris Therapeutics to Present at Upcoming Investor Conferences GlobeNewswire |
| Nov-07-19 04:01PM | Aclaris Therapeutics Reports Third Quarter 2019 Financial Results and Provides Business Highlights and an Update on R&D Programs GlobeNewswire |
| Oct-31-19 04:01PM | Aclaris Therapeutics to Announce Third Quarter 2019 Financial Results on November 7, 2019 GlobeNewswire |
| Oct-29-19 10:33AM | Aclaris Therapeutics (ACRS) May Report Negative Earnings: Know the Trend Ahead of Q3 Release Zacks +14.46% |
| Oct-25-19 07:12AM | The Daily Biotech Pulse: Melinta Crosses FDA Hurdle But Sees Liquidity Pushback, Positive Readout For Aclaris Wart Drug Benzinga +5.95% |
| Oct-24-19 04:01PM | Aclaris Therapeutics A-101 45% Topical Solution Meets Primary and All Secondary Efficacy Endpoints in Second Successful Pivotal Phase 3 Clinical Trial for the Treatment of Common Warts (THWART-1) GlobeNewswire |
| Oct-17-19 09:46AM | Company News for Oct 17, 2019 Zacks +6.41% |
| Oct-14-19 10:28AM | Aclaris Divests Rhofade to EPI Health for $55M, Shares Up Zacks |
| Oct-11-19 11:46AM | Wayne biopharma sells rosacea therapy in deal that could bring in $55M American City Business Journals +19.33% |
| Oct-10-19 04:02PM | Aclaris Therapeutics Announces Divestiture of RHOFADE® GlobeNewswire |
| Oct-09-19 07:58AM | The Daily Biotech Pulse: FDA Approves Clinuvel Drug, Aclaris Files Patent Lawsuit Against Taro, Viela Out-Licenses Autoimmune Disorder Drug Benzinga |
| Oct-08-19 05:01PM | Aclaris Therapeutics Files Patent Infringement Lawsuit Against Taro Pharmaceuticals, Inc. for Filing an ANDA for a Generic Version of RHOFADE® (oxymetazoline hydrochloride) cream, 1% GlobeNewswire |
| 01:42PM | Edited Transcript of ACRS earnings conference call or presentation 8-Aug-19 9:00pm GMT Thomson Reuters StreetEvents |
| Oct-07-19 07:25AM | Does Market Volatility Impact Aclaris Therapeutics, Inc.'s (NASDAQ:ACRS) Share Price? Simply Wall St. |
| Oct-06-19 10:00AM | Bragar Eagel & Squire is Investigating Certain Officers and Directors of PriceSmart, Pyxus, Aclaris Therapeutics, and Zimmer Biomet Holdings and Encourages Investors to Contact the Firm GlobeNewswire |
| Oct-03-19 07:28AM | Top Ranked Momentum Stocks to Buy for October 3rd Zacks |
| Sep-30-19 12:15PM | FINAL DEADLINE TODAY: The Schall Law Firm Announces it is Investigating Claims Against Aclaris Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm ACCESSWIRE -9.24% |
| 10:44AM | FINAL SEPT. 30 DEADLINE: ROSEN, A TOP RANKED LAW FIRM, Reminds Aclaris Therapeutics, Inc. Investors of Important Deadline in Securities Class Action ACRS GlobeNewswire |
| Sep-28-19 06:30PM | DEADLINE MONDAY: The Schall Law Firm Announces it is Investigating Claims Against Aclaris Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm ACCESSWIRE |
| 10:00AM | DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Aclaris Therapeutics, Inc. (NYSE: ACRS) and Encourages Aclaris Investors to Contact the Firm Business Wire |
| Sep-27-19 08:15PM | FINAL DEADLINE MONDAY: The Schall Law Firm Announces it is Investigating Claims Against Aclaris Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm ACCESSWIRE |
| 03:00PM | Sarepta Therapeutics, Inc. (SRPT), Aclaris Therapeutics, Inc. (ACRS) & Canada Goose Holdings Inc. (GOOS) - Class Action Update - Bronstein, Gewirtz & Grossman, LLC GlobeNewswire |
| 12:21PM | Top Ranked Momentum Stocks to Buy for September 27th Zacks |
| 11:00AM | DEADLINE ALERT for ACRS, GTT, JE, and NKTR: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders GlobeNewswire |
| 10:36AM | Sarepta Therapeutics, Inc. (SRPT), Aclaris Therapeutics, Inc. (ACRS) & Canada Goose Holdings Inc. (GOOS) - Class Action - Bronstein, Gewirtz & Grossman, LLC ACCESSWIRE |
| Sep-26-19 04:45PM | SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Aclaris Therapeutics Inc. of Class Action Lawsuit and Upcoming Deadline - ACRS PR Newswire -11.65% |
| 04:45PM | SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Aclaris Therapeutics Inc. of Class Action Lawsuit and Upcoming Deadline - ACRS CNW Group |
| 11:17AM | Pawar Law Group Reminds Investors of September 30 Deadline in Securities Class Action Lawsuit Against Aclaris Therapeutics, Inc. ACRS GlobeNewswire |
| 08:19AM | Aclaris Therapeutics, Inc. (ACRS) Shares March Higher, Can It Continue? Zacks |
| Sep-25-19 08:48PM | DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Aclaris Therapeutics, Inc. (NASDAQ: ACRS) and Encourages Aclaris Investors to Contact the Firm PR Newswire +6.83% |
| 03:38PM | ACLARIS DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Aclaris Therapeutics, Inc. To Contact The Firm Newsfile |
| 03:15PM | 5-Day Deadline Alert: The Schall Law Firm Announces it is Investigating Claims Against Aclaris Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm ACCESSWIRE |
| 11:00AM | Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Aclaris Therapeutics, Inc. GlobeNewswire |
| 10:35AM | Sarepta Therapeutics, Inc. (SRPT), Aclaris Therapeutics, Inc. (ACRS) & Canada Goose Holdings Inc. (GOOS) - Class Action Update - Bronstein, Gewirtz & Grossman, LLC ACCESSWIRE |
| 09:00AM | Aclaris (ACRS) Moves to Buy: Rationale Behind the Upgrade Zacks |
| Sep-24-19 09:10PM | 6-Day Deadline Alert: The Schall Law Firm Announces it is Investigating Claims Against Aclaris Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm ACCESSWIRE |
| 03:15PM | SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Aclaris Therapeutics Inc. of Class Action Lawsuit and Upcoming Deadline ACRS GlobeNewswire |
| 03:09PM | Zhang Investor Law Reminds Investors of Sept. 30 Deadline in Securities Class Action Lawsuit Against Aclaris Therapeutics, Inc. ACRS GlobeNewswire |
| 01:05PM | LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Aclaris Therapeutics, Inc. To Contact The Firm Newsfile |
| Sep-23-19 10:34AM | Sarepta Therapeutics, Inc. (SRPT), Aclaris Therapeutics, Inc. (ACRS) & Canada Goose Holdings Inc. (GOOS) - Class Action Alert - Bronstein, Gewirtz & Grossman, LLC ACCESSWIRE -9.51% |
| 09:35AM | 7-DAY DEADLINE ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Aclaris Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm GlobeNewswire |
| Sep-20-19 03:00PM | GTT Communications, Inc. (GTT), Sarepta Therapeutics, Inc. (SRPT) & Aclaris Therapeutics, Inc. (ACRS) - Class Action Alert - Bronstein, Gewirtz & Grossman, LLC GlobeNewswire |
| 11:31AM | GLOBALLY RECOGNIZED ROSEN LAW FIRM Reminds Aclaris Therapeutics, Inc. Investors of Important September 30th Deadline in Securities Class Action ACRS GlobeNewswire |
| 11:00AM | Deadline Reminder: The Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Aclaris Therapeutics, Inc. GlobeNewswire |
| 10:44AM | GTT Communications, Inc. (GTT), Sarepta Therapeutics, Inc. (SRPT) & Aclaris Therapeutics, Inc. (ACRS) - Class Actions - Bronstein, Gewirtz & Grossman, LLC ACCESSWIRE |
| Sep-19-19 07:40PM | IMPORTANT SEPTEMBER DEADLINE: The Schall Law Firm Announces it is Investigating Claims Against Aclaris Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm ACCESSWIRE -14.72% |
| 01:30PM | SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Aclaris Therapeutics Inc. of Class Action Lawsuit and Upcoming Deadline - ACRS ACCESSWIRE |
| 11:30AM | DEADLINE: Pawar Law Group Reminds Investors of September 30 Deadline in Securities Class Action Lawsuit Against Aclaris Therapeutics, Inc. - ACRS ACCESSWIRE |
| Sep-18-19 07:51PM | Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Aclaris Therapeutics, Carbonite, GTT Communications, and Just Energy and Encourages Investors to Contact the Firm GlobeNewswire -9.44% |
| 05:45PM | IMPORTANT DEADLINE REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Aclaris Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm ACCESSWIRE |
| 12:23PM | A Look At Benzinga Pro's Most-Searched Tickers For September 18, 2019 Benzinga |
| 10:42AM | GTT Communications, Inc. (GTT), Sarepta Therapeutics, Inc. (SRPT) & Aclaris Therapeutics, Inc. (ACRS) - Class Action Alert - Bronstein, Gewirtz & Grossman, LLC ACCESSWIRE |
| Sep-17-19 08:49PM | SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Aclaris Therapeutics Inc. of Class Action Lawsuit and Upcoming Deadline ACRS GlobeNewswire +63.64% |
| 02:45PM | SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Aclaris Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm ACCESSWIRE |
| 12:29PM | A Look At Benzinga Pro's Most-Searched Tickers For September 17, 2019 Benzinga |
| 11:15AM | Why Microcap Biotech Aclaris Is Rallying Benzinga |
| 07:23AM | The Daily Biotech Pulse: Acceleron Shelves Muscular Dystrophy Drug Trial, Aclaris Aces Late-Stage Study Benzinga |
| 07:00AM | Aclaris Therapeutics to Hold R&D Day GlobeNewswire |
| Sep-16-19 04:55PM | ONGOING INVESTIGATION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Aclaris Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm ACCESSWIRE +6.80% |
| 04:15PM | Aclaris Therapeutics A-101 45% Topical Solution Meets Primary and All Secondary Efficacy Endpoints in Pivotal Phase 3 Trial for the Treatment of Common Warts (THWART-2) GlobeNewswire |
| 10:41AM | GTT Communications, Inc. (GTT), Sarepta Therapeutics, Inc. (SRPT) & Aclaris Therapeutics, Inc. (ACRS) - Class Action Update - Bronstein, Gewirtz & Grossman, LLC ACCESSWIRE |
| 09:38AM | ACRS NOTICE, ROSEN, A LEADING FIRM Reminds Aclaris Therapeutics, Inc. Investors of Important September 30th Deadline in Securities Class Action - ACRS ACCESSWIRE |
| 09:35AM | UPCOMING DEADLINE NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Aclaris Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm GlobeNewswire |
| 09:14AM | LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Aclaris Therapeutics, Inc. To Contact The Firm GlobeNewswire |
| Sep-14-19 07:02AM | SHAREHOLDER NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Aclaris Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm ACCESSWIRE |
| Sep-13-19 03:45PM | Zhang Investor Law Reminds Investors of Sept. 30 Deadline in Securities Class Action Lawsuit Against Aclaris Therapeutics, Inc. - ACRS ACCESSWIRE |
| 03:15PM | INVESTOR ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Aclaris Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm ACCESSWIRE |
| 03:00PM | SHAREHOLDER ALERT - Aclaris Therapeutics, Inc. (ACRS) - Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Class Action and Lead Deadline: September 30, 2019 GlobeNewswire |
| 10:05AM | SHAREHOLDER ALERT - Aclaris Therapeutics, Inc. (ACRS) - Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Class Action and Lead Deadline: September 30, 2019 ACCESSWIRE |
| Sep-12-19 09:10PM | IMPORTANT SEPTEMBER DEADLINE: The Schall Law Firm Announces it is Investigating Claims Against Aclaris Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm ACCESSWIRE |
| 06:20PM | GLOBALLY RECOGNIZED ROSEN LAW FIRM Reminds Aclaris Therapeutics, Inc. Investors of Important September 30th Deadline in Securities Class Action ACRS Business Wire |
| 02:52PM | SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Aclaris Therapeutics Inc. of Class Action Lawsuit and Upcoming Deadline ACRS GlobeNewswire |
| Sep-11-19 09:20PM | IMPORTANT DEADLINE NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Aclaris Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm ACCESSWIRE |
| 10:15AM | INVESTOR ALERT - Aclaris Therapeutics, Inc. (ACRS) - Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Class Action and Lead Deadline: September 30, 2019 ACCESSWIRE |
| Sep-10-19 07:30PM | Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against National General, Mallinckrodt, Oasmia Pharmaceutical, and Aclaris Therapeutics and Encourages Investors to Contact the Firm GlobeNewswire +7.69% |
| 06:20PM | SEPTEMBER DEADLINE ALERT: The Schall Law Firm Announces it is Investigating Claims Against Aclaris Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm ACCESSWIRE |
| 03:00PM | NATIONALLY RANKED ROSEN LAW FIRM Reminds Aclaris Therapeutics, Inc. Investors of Important September 30th Deadline in Securities Class Action; ENCOURAGES INVESTORS WITH LOSSES IN EXCESS OF $100K TO CONTACT THE FIRM ACRS GlobeNewswire |
| 11:36AM | LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Aclaris Therapeutics, Inc. To Contact The Firm GlobeNewswire |
| 10:07AM | Why Aclaris is laying off half of its staff American City Business Journals |
| 09:15AM | ACRS DEADLINE ALERT: Pawar Law Group Announces a Securities Class Action Lawsuit Against Aclaris Therapeutics, Inc. - ACRS ACCESSWIRE |
| Sep-09-19 12:55PM | Shareholder Alert: Robbins Arroyo LLP Reminds Shareholders That Aclaris Therapeutics, Inc. (ACRS) Sued for Misleading Shareholders Business Wire |
| 11:25AM | UPCOMING DEADLINE REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Aclaris Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm GlobeNewswire |
| 09:47AM | Chester County biopharmaceutical firm cutting 86 jobs American City Business Journals |
| Sep-06-19 10:55PM | ACRS DEADLINE: Zhang Investor Law Reminds Investors of Sept. 30 Deadline in Securities Class Action Lawsuit Against Aclaris Therapeutics, Inc. - ACRS ACCESSWIRE +9.68% |
|
|
|
|
| Aclaris Therapeutics, Inc., a biopharmaceutical company, focuses on identifying, developing, and commercializing various therapies for dermatological and immuno-inflammatory diseases in the United States. It operates in two segments, Therapeutics and Contract Research. The company offers ESKATA, a formulation of high-concentration hydrogen peroxide topical solution for raised seborrheic keratosis, a common non-malignant skin tumor; and RHOFADE, an oxymetazoline hydrochloride cream. It is also developing A-101, a high-concentration formulation of hydrogen peroxide that is in Phase III clinical trial for common warts; and ATI-501 and ATI-502 Janus kinase (JAK) inhibitors, which are in Phase II clinical trials for alopecia areata (AA) and other dermatological indications. In addition, the company's products under development include ATI-450 an investigational oral, novel, small molecule selective MK2 inhibitor compound, for the treatment of rheumatoid arthritis; ATI-1777 soft inhibitor for atopic dermatitis; and ATI-2138, an investigational oral ITK/TXK/JAK3, or ITJ, inhibitor compound, for the treatment of psoriasis inflammatory bowel disease. Further, it provides contract research laboratory services. Aclaris Therapeutics, Inc. has a license and collaboration agreement with Rigel Pharmaceuticals, Inc. for the development and commercialization of JAK inhibitors. The company was founded in 2012 and is headquartered in Wayne, Pennsylvania. |
|
| Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
| Flynn James E | 10% Owner | Jun 27 | Sale | 2.69 | 699,475 | 1,882,077 | 964,101 | Jul 01 05:01 PM | | Flynn James E | 10% Owner | Jun 26 | Sale | 4.50 | 1,704 | 7,671 | 1,072,775 | Jun 26 05:52 PM | | Flynn James E | 10% Owner | Jun 25 | Sale | 4.51 | 51,484 | 232,136 | 1,073,127 | Jun 25 06:31 PM | | Flynn James E | 10% Owner | Jun 24 | Sale | 4.52 | 63,240 | 286,003 | 1,083,761 | Jun 25 06:31 PM | | Flynn James E | 10% Owner | Jun 21 | Sale | 4.62 | 339,537 | 1,567,099 | 1,096,824 | Jun 25 06:31 PM | | Flynn James E | 10% Owner | May 10 | Sale | 6.05 | 180,565 | 1,092,274 | 1,166,959 | May 13 05:24 PM | | Flynn James E | 10% Owner | May 09 | Sale | 6.16 | 434,145 | 2,673,248 | 1,238,828 | May 13 05:24 PM |
|
|
|
|
|
|
